Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 12/20 | 0.34 |
| ▸ | FGFR2 | P21802 | 12/20 | 0.34 |
| ▸ | FGFR4 | P22455 | 12/20 | 0.34 |
| ▸ | FGFR3 | P22607 | 12/20 | 0.34 |
| ▸ | KDR | P35968 | 12/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.33 |
| ▸ | FLT3 | P36888 | 4/20 | 0.32 |
| ▸ | MAOB | P27338 | 2/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20908298 | 1.00 | FGFR1 (0.34) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL21150320 | 0.83 | MKNK1 (0.34) | HSP90AA1 | |
| SCHEMBL20908295 | 0.80 | MEN1 (0.32) | — | |
| SCHEMBL29640278 | 0.80 | MEN1 (0.32) | — | |
| SCHEMBL28402032 | 0.80 | MEN1 (0.32) | — | |
| SCHEMBL20907701 | 0.79 | MEN1 (0.34) | — | |
| SCHEMBL23114938 | 0.75 | KCNH2 (0.34) | — | |
| SCHEMBL20907705 | 0.75 | KCNH2 (0.34) | — | |
| SCHEMBL20908241 | 0.75 | POLQ (0.34) | — | |
| SCHEMBL23115147 | 0.75 | POLQ (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774053-B2 | HIV protease inhibitors | GILEAD SCIENCES, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190210978-A1 | HIV PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774053-B2 | HIV protease inhibitors | PRSS1, SERPINB1, FURIN | FGFR1 3083/4885FGFR2 4620/4885FGFR4 4058/4885 |
| US-20190210978-A1 | HIV PROTEASE INHIBITORS | PRSS1, SERPINB1, HPN | FGFR1 3306/4885FGFR2 4456/4885FGFR4 4102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.